Mexico - Delayed Quote MXN

Bristol-Myers Squibb Company (BMY.MX)

Comparer

1,225.14

-24.86

(-1.99%)

À la clôture : January 31 at 2:53:22 PM CST

No Tool

Measure

UNDO

Redo

Tous

Favoris

Texte

Statistiques

Éléments techniques

Fibonacci

Marquages

Lignes

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Chargement du graphique de BMY.MX

Afficher davantage

Top Dividend Stocks Yielding As High As 5%: Fidelity

Stocks to watch next week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

$Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma$

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bristol-Myers Squibb Company (BMY.MX)

Comparaisons

Indicateurs

Éléments techniques

Événements d’entreprise

1.08%

5.34%

17.24%

33.02%

5.34%

44.82%

2.39%

337.41%

Derniers articles: BMY.MX

Top Dividend Stocks Yielding As High As 5%: Fidelity

Stocks to watch next week: Amazon, Palantir, Disney, Novo Nordisk and AstraZeneca

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?

Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why Bristol-Myers Squibb Company (BMY) Is the Best Blue Chip Stock to Buy Under $100?

Bristol-Myers Squibb (BMY): Cramer’s Old-School Move for DeepSeek Market Jitters

Bristol-Myers Squibb Insider Ups Holding During Year